TKNO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• Clinical Solutions revenue was $2.4 million for the three months ended June 30, 2026, an increase of $0.4 million, or 17.9%, compared to $2.1 million for the three months ended June 30, 2025. The increase in Clinical Solutions revenue was attributable to an increased number of customers, partially o…

• Gross profit percentage was 40.1% and 38.7% for the three months ended June 30, 2026 and 2025, respectively. The increase in gross profit percentage was primarily driven by higher revenue, partially offset by higher fixed cost absorption into cost of goods sold from faster finished goods inventory t…

• Total other expenses, net was $0.3 million for the three months ended June 30, 2026, compared to $0.2 million for the three months ended June 30, 2025. The increase in total other expenses, net was primarily attributable to lower interest income.

• Comparison of the Six Months Ended June 30, 2026, and Six Months Ended June 30, 2025

• The following tables set forth our results of operations for the six months ended June 30, 2026 and 2025 (dollars in thousands):

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• Clinical Solutions revenue was $2.1 million for the three months ended March 31, 2026, an increase of $1.0 million, or 84.6%, compared to $1.2 million for the three months ended March 31, 2025. The increase in Clinical Solutions revenue was attributable to an increased number of customers and, to a …

• Gross profit percentage was 34.2% and 30.7% for the three months ended March 31, 2026 and 2025, respectively. The increase in gross profit was primarily driven by higher revenue.

• Total other (expenses) income, net was an expense of $0.2 million for the three months ended March 31, 2026, compared to income of $0.3 million for the three months ended March 31, 2025. The increase in total other expense, net was primarily attributable to the $0.5 million adjustment recognized on …

• cash requirements from known contractual obligations and commitments relate primarily to operating leases for our office, manufacturing, warehouse, and distribution facilities at March 31, 2026. See “Notes to Financial Statements—Note 9. Leases,” for a discussion of our lease obligations reflected o…

• In addition to our existing cash and cash equivalents and short-term investments, our principal source of liquidity is our credit facility. On March 3, 2025, we entered into the Second Amended and Restated Credit Agreement with MidCap Financial (Midcap) Trust which provides for loan commitments in a…

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• The use of artificial intelligence (AI) and other emerging technologies in our operations may expose us to additional operational, competitive, regulatory, legal, cybersecurity, intellectual property, compliance, and other risks.

• We are evaluating and may increasingly incorporate artificial intelligence ("AI"), machine learning, and other emerging technologies into various facets of our operations, including our manufacturing processes, quality systems, and customer-facing activities. While we believe these technologies have…

• The algorithms and models underlying AI systems may have limitations, including biases, errors, insufficient or erroneous training data, or an inability to handle certain data types or scenarios. AI-generated content, analyses, or recommendations we utilize could prove inadequate or produce unintend…

• The regulatory landscape governing the use of AI is rapidly evolving, particularly in California, where we are headquartered, and more broadly across the United States and internationally. California has been among the most active jurisdictions in developing AI-related legislation and regulation, in…

• The use of AI and related technologies also introduces cybersecurity risks, including vulnerabilities in third-party AI tools or platforms we may adopt and risks related to the integrity or confidentiality of data used to train or operate such systems. A breach or failure of any AI-related system co…